---
layout: default
title: Aluminum Nitrate
parent: 僅模型預測 (L5)
nav_order: 279
evidence_level: L5
indication_count: 0
---

# Aluminum Nitrate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Aluminum Nitrate: Insufficient Data for Drug Repurposing Evaluation

## One-Sentence Summary

Aluminum Nitrate is a chemical compound with no currently registered pharmaceutical indications in Taiwan or internationally. The TxGNN model did not generate any repurposing predictions for this compound, and no supporting clinical or literature evidence is available. **This evaluation cannot proceed in its standard form due to critical data gaps across all dimensions.**

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | None |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — Model prediction only; in this case not even a prediction was generated |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

## Why This Evaluation Cannot Proceed

Aluminum Nitrate (Al(NO₃)₃) is an inorganic aluminum salt primarily known as an industrial and laboratory chemical reagent. Unlike conventional pharmaceutical compounds, it does not have an established mechanism of action in human therapeutics, nor does it carry a DrugBank identifier in this evidence pack.

The TxGNN knowledge graph relies on a compound's DrugBank entry to anchor it within the drug–disease relation network. Without a DrugBank ID, the model cannot map the compound to any node in the graph, which explains why `predicted_indications` returned an empty result set. This is a structural limitation, not a model failure.

There is no original therapeutic indication on record — meaning there is no "source indication" from which a repurposing trajectory can be drawn. The standard evaluation framework (original indication → mechanistic bridge → predicted indication) therefore has no starting point.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
There are no TxGNN predictions, no original pharmaceutical indications, no DrugBank ID, and no clinical or literature evidence for Aluminum Nitrate as a therapeutic agent. The evaluation pipeline has no data to evaluate.

**To proceed, the following is needed:**

- **Confirm compound identity**: Verify whether the intended query is Aluminum Nitrate the industrial salt, or a derivative/formulation (e.g., basic aluminum compounds used in antiperspirants or topical astringents) that may carry a DrugBank entry
- **Obtain DrugBank ID**: Query DrugBank API to confirm whether any pharmaceutical form of aluminum nitrate is indexed; if not, the compound is outside the TxGNN prediction scope
- **Establish a therapeutic context**: If a specific clinical use case (e.g., topical astringent, hemostatic agent) is hypothesized, provide that indication as a manual starting point for a targeted literature review
- **Re-run TxGNN pipeline**: Once a valid DrugBank ID is obtained, re-execute the KG and DL prediction pipelines to generate repurposing candidates
- **Basic toxicology data**: Obtain MSDS/safety data and any available human exposure records before any clinical consideration
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

